Podcast
Questions and Answers
What is the focus of the study mentioned in the text?
What is the focus of the study mentioned in the text?
- Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies
- Drug-induced dermatomyositis after zoledronic acid
- Associations of tumor necrosis factor alpha and HLA polymorphisms (correct)
- Review of drug-induced dermatomyositis
Which publication discusses drug-induced dermatomyositis after zoledronic acid?
Which publication discusses drug-induced dermatomyositis after zoledronic acid?
- Australas J Dermatol 2012;53:e73–5 (correct)
- Rheumatology (Oxford) 2009;48:607–12
- J Cutan Pathol 2008;35:74–81
- JAMA Dermatol 2015;151:195–9
Who authored the review of drug-induced dermatomyositis discussed in the text?
Who authored the review of drug-induced dermatomyositis discussed in the text?
- Werth VP, Callen JP, Ang G, Sullivan KE (correct)
- Gunawardena H, Betteridge ZE, McHugh NJ
- Tong PL, Yu LL, Chan JJ
- Sheik Ali S, Goddard AL, Luke JJ
What is the clinical significance of antinuclear antibodies?
What is the clinical significance of antinuclear antibodies?
What percentage of dermatomyositis patients have clinically amyopathic disease?
What percentage of dermatomyositis patients have clinically amyopathic disease?
According to the revised classification proposed by Sontheimer, is muscle involvement still required for a definitive diagnosis of amyopathic forms of dermatomyositis?
According to the revised classification proposed by Sontheimer, is muscle involvement still required for a definitive diagnosis of amyopathic forms of dermatomyositis?
In adults, how does dermatomyositis affect women compared to men?
In adults, how does dermatomyositis affect women compared to men?
How can adult-onset and juvenile-onset amyopathic DM and hypomyopathic DM be further subcategorized as?
How can adult-onset and juvenile-onset amyopathic DM and hypomyopathic DM be further subcategorized as?
What is the recommended pre-treatment warning for this medication?
What is the recommended pre-treatment warning for this medication?
Which treatment approach is commonly used for cutaneous dermatomyositis that is refractory to antimalarials?
Which treatment approach is commonly used for cutaneous dermatomyositis that is refractory to antimalarials?
Which therapy is NOT mentioned as a potential treatment for calcinosis cutis?
Which therapy is NOT mentioned as a potential treatment for calcinosis cutis?
How does early and aggressive therapy of juvenile dermatomyositis affect the risk of calcinosis cutis?
How does early and aggressive therapy of juvenile dermatomyositis affect the risk of calcinosis cutis?
Flashcards are hidden until you start studying
